Download presentation
Presentation is loading. Please wait.
Published byΚλωθώ Ζάχος Modified over 5 years ago
1
Elevation of Serum Krebs von den Lunge–6 Levels in Patients With Tubulointerstitial Nephritis and Uveitis Syndrome Satoru Kase, MD, PhD, Nobuyoshi Kitaichi, MD, PhD, Kenichi Namba, MD, PhD, Akiko Miyazaki, MD, Kazuhiko Yoshida, MD, PhD, Kenji Ishikura, MD, Masahiro Ikeda, MD, Taiji Nakashima, MD, Shigeaki Ohno, MD, PhD American Journal of Kidney Diseases Volume 48, Issue 6, Pages (December 2006) DOI: /j.ajkd Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions
2
Fig 1 Scattergram of serum KL-6 and urinary β2-microglobulin levels in all patients with TINU syndrome and uveitis from other causes. The X-axis indicates urinary β2-microglobulin levels (mg/L), and the Y-axis shows serum KL-6 levels (U/mL). American Journal of Kidney Diseases , DOI: ( /j.ajkd ) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions
3
Fig 2 Serial observations of serum KL-6 (S-KL-6) and urinary β2-microglobulin (U-b2MG) levels in patients with TINU syndrome (patients 2, 13, 16, and 17). The Y-axis on the left shows serum KL-6 levels (U/mL). The Y-axis on the right indicates urinary β2-microglobulin levels (mg/L). After the beginning of treatment, serum KL-6 (rectangle) and urinary β2-microglobulin (circle) levels decreased simultaneously. American Journal of Kidney Diseases , DOI: ( /j.ajkd ) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions
4
Fig 3 (A) Hematoxylin and eosin staining and (B-D) immunodetection of KL-6 in renal tissues obtained by biopsy in patients with TINU syndrome. (A) Renal biopsy specimen shows that mononuclear cells infiltrated the stroma and some renal tubes were atrophic without involvement of the glomerulus. (B-D) Immunoreactivity for KL-6 was strong in renal distal tubules, but absent in the glomerulus (arrow). American Journal of Kidney Diseases , DOI: ( /j.ajkd ) Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.